death compared with patients without kidney disease. [2] [3] [4] [5] [6] Paradoxically, patients on dialysis are also at an increased risk of thrombosis. 7 Therefore, research devoted to defining the optimal antithrombotic regimen during PCI in this population is needed. Unfortunately, due to the under-representation or exclusion of patients with kidney disease from cardiovascular randomized clinical trials, 8 there remains a remarkable dearth of evidence guiding treatment in this population.
Further complicating this issue is the fact that many medications are metabolized and excreted by the kidney, thereby placing these patients at risk of receiving contraindicated medications. [9] [10] [11] One such drug is eptifibatide-a glycoprotein IIb/IIIa inhibitor (GPI) that has been shown to reduce ischemic complications during and after PCI. 12, 13 Per the manufacturer's labeling, eptifibatide is contraindicated in dialysis as its "safety and efficacy" has not been established in these patients. 14 In a landmark paper by Tsai et al, 9 the authors demonstrated that nearly a quarter of dialysis patients undergoing PCI received eptifibatide or low molecular weight heparin, two contraindicated medications in dialysis. Furthermore, they found that administration of contraindicated medications was associated with an increased risk of in-hospital major bleeding. 9 Due to this important and alarming statistic, most would agree that efforts should be made to reduce the use of contraindicated medications during PCI in patients on dialysis. As such, we sought to evaluate the contemporary use of eptifibatide in dialysis patients undergoing PCI, and to assess the comparative safety of eptifibatide compared with abciximab in these patients using a multicenter registry in the state of Michigan.
2 | METHODS
| Study population
We performed a retrospective analysis on data from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2), a quality improvement group and regional registry of all patients undergoing PCI in the state of Michigan. A more detailed description of the registry, including data collection and auditing practices, has been described previously. 15, 16 This is a prospective, multicenter, statewide registry of patients undergoing PCI at all non-federal hospitals in
Michigan. For the current study, consecutive patients undergoing PCI between January 2010 and September 2015 at 47 hospitals were included.
| Study groups
We divided patients into two groups by the use of renal dialysis.
Patients were considered to require dialysis if they were "undergoing either hemodialysis or peritoneal dialysis on an ongoing basis as a result of renal failure" prior to PCI. 17 To compare the safety of abciximab and eptifibatide, we stratified dialysis patients by these two drugs. Next, we excluded patients who received a GPI with any anticoagulant other than unfractionated heparin (UFH) to reduce bias associated with differential anticoagulant administration. Patients receiving low molecular weight heparin or fondaparinux were excluded because low molecular weight heparin is contraindicated in dialysis and fondaparinux is rarely used during PCI. We excluded patients who received bivalirudin and a GPI because GPIs are frequently administered with bivalirudin as a "bailout" strategy for the treatment of suboptimal procedural results or complications, thereby representing a high-risk subgroup of patients. 18 Finally, patients who underwent PCI without recorded femoral or radial access were also excluded.
| Clinical outcomes
All outcomes were measured during the incident hospitalization when PCI was performed. In-hospital outcomes included the need for transfusion, bleeding, presumed major bleeding, repeat PCI, and mortality due to any cause. The need for transfusion was defined as the receipt of ≥1 unit of red blood cell or whole blood transfusion after PCI. Bleeding, as defined by the National Cardiovascular Data
Registry (NCDR), included an event within 72 h of PCI that was associated with any of the following: a drop in hemoglobin ≥3 g/dL;
transfusion of whole blood or packed red blood cells; an intervention or surgery at the site of bleeding to reverse, stop, or correct the bleeding. 17 Presumed major bleeding was defined as a drop in hemoglobin >5 g/dL. Repeat PCI was defined as repeat intervention during the incident hospitalization on the lesion that was initially treated.
| Statistical analysis
Propensity scores were estimated using logistic regression models adjusting for baseline demographic and patient clinical variables (Supplemental Table S1 ). Using optimal full matching methods, we created matched patient strata of patients who were generally similar in terms of baseline characteristics. These strata contained varying numbers of patients with (cases) and without (controls) the covariate of interest (abciximab or eptifibatide). 19 Optimal full matching allows treatment group members to share control group members resulting in the use of many more subjects than would be the case if pairwise or "greedy" matching were used. 19 We required exact matching on race Patients who received eptifibatide were more frequently white (66.7%
vs. 45.0%; P <0.001); had higher pre-procedural hemoglobin levels (11.3 g/dL vs. 10.7 g/dL; P <0.001); and less frequently had a history of myocardial infarction (36.5% vs. 52.0%; P = 0.005) ( Table 2 ). Prior to matching, there were no significant differences among in-hospital outcomes between patients treated with eptifibatide compared with abciximab: need for transfusion (18.8% vs. 18.0%; P = 0.86), bleeding (10.2% vs. 10.0%; P = 0.96), major bleeding (1.3% vs. 2.0%; P = 0.60),
repeat PCI (1.3% vs. 1.0%; P = 0.81), and death (4.4% vs. 8.0%; P = 0.15).
| Outcomes
After optimal full matching, the ASDs were <10% for most matched variables ( Fig. 2) , indicating globally similar baseline characteristics within matched strata ( Table 2 ). Of note, the pre-procedural rate of clopidogrel, prasugrel, and ticagrelor administration was 79.2%, 8.9%, and 4.0% for patients receiving eptifibatide and 74.5%, 6.4%, and 3.3%
for patients receiving abciximab, respectively (Table 2 ). There were no significant differences in the adjusted rates and odds of in-hospital outcomes between patients receiving eptifibatide compared with abciximab, respectively: the need for transfusion (14 1.53; 95%CI: 0.26-9.05; P = 0.64) (Fig. 3) .
Of the 384 patients who received eptifibatide, 224 (58.3%) received the medication post-procedurally as well as intraprocedurally whereas the remainder only received it intraprocedurally. In an unadjusted analysis, of the 224 patients who received eptifibatide in the intra-and post-procedural period 13 (5.8%) patients died, whereas only 4 of the 140 patients (2.5%) who received eptifibatide only during the procedure died. Among the patients treated with abciximab, there were four deaths among patients who received the medication intra-procedurally and post-procedurally (n/N = 4/61; 6.6%), and four deaths among those treated with abciximab only during the procedure (n/N = 4/39; 10.3%). The small number of patients in each group limited our ability to further investigate the effect of post-procedural GPI administration on outcomes.
| DISCUSSION
Using a large regional registry of patients undergoing PCI, we evaluated the safety of two commonly used GPIs, abciximab and eptifibatide, in dialysis patients undergoing PCI. Our study has three major findings.
First, despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more often than abciximab. Second, after propensity matching there were no significant differences in important in-hospital outcomes between the two drugs. Third, the frequency of GPI administration among dialysis patients was generally low; however, the rates of bleeding in this select population were high.
The use of GPIs around the time of PCI has been shown to reduce ischemic complications when added to UFH, although often at the expense of increased bleeding complications. 13, 21, 22 Therefore, clinical practice guidelines recommend carefully considering GPI administration in populations at a high risk of bleeding events, like patients with kidney disease. 18 Nevertheless, in a landmark paper, Tsai et al 9 discovered that nearly a quarter of patients on dialysis undergoing PCI were treated with a contraindicated medication such as eptifibatide. 9 Despite this highly publicized and alarming statistic, we found that eptifibatide continues to be the most frequently prescribed GPI among dialysis patients undergoing PCI.
The reasons why eptifibatide continues to be used when contraindicated in dialysis remains unclear, though we speculate that many factors may play a role. First, eptifibatide is less expensive than abciximab which may drive the increased utilization of eptifibatide. 23 Furthermore, eptifibatide may be more readily available for emergent administration in the catheterization lab. Second, physicians may not be aware of the contraindications to eptifibatide.
If this is the case, clinically useful electronic medical records should play an important role in reducing this type of error.
The benefit of GPIs in the management of coronary artery disease was demonstrated through a series of large randomized controlled trials which found a 33% reduction in the risk of death, nonfatal MI, or urgent revascularization at 30 days among patients undergoing PCI. 24 These initial trials primarily compared GPIs to placebo. The TARGET trial was a multicenter evaluation of tirofiban versus abciximab among patients undergoing PCI with the intent to perform stenting. 25 The primary endpoint was a composite of death, nonfatal MI, or urgent target-vessel revascularization at 30 days. The investigators discovered a higher rate of the primary endpoint among patients treated with tirofiban compared with abxicimab (7.6% vs. 6.0%; hazard ratio = 1.26;
95%CI: 1.01-1.57; P = 0.038). However, there was a higher rate of 2.8%; P < 0.001), thus demonstrating the careful balance between ischemic and bleeding complications with these drugs. 25 The current study also demonstrates the balance between these two complications. Patients treated with eptifibatide had lower adjusted rates of bleeding complications but a higher rate of repeat PCI (ie, ischemic complication) compared with abciximab; however, these differences were not statistically significant. 
FIGURE 2
Plot of absolute standardized differences before and after matching. Absolute standardized differences before and after matching in dialysis patients receiving eptifibatide compared with abciximab. CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVD, cerebrovascular disease; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; Sx, symptoms FIGURE 3 Adjusted event rates of in-hospital outcomes in the matched cohort. Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients receiving eptifibatide compared with abciximab. All comparisons are non-significant (P > 0.2 for all). PCI, percutaneous coronary intervention Although we were unable to determine the reasons for the continued use of eptifibatide in this high-risk population, it is important to note that we did not find significant differences in the rates of inhospital bleeding, transfusion, or mortality among dialysis patients who received eptifibatide compared with abciximab. 
| Limitations
There are several important limitations that deserve specific mention.
First, as previously noted, we were unable to determine the rationale for GPI administration which may have resulted in inadequate matching. For example, a modest proportion of patients may have received eptifibatide in a provisional fashion due to unmeasured circumstances that occurred during PCI (ie, extreme thrombus burden, ongoing ischemia, etc.). These factors may represent confounding variables associated with the nonrandom administration of these drugs. Although we attempted to account for the non-random administration of the studied medications through propensity-matching techniques, due to the retrospective nature of this study, we were unable to account for all potential confounders. Second, wide confidence intervals around the point estimates for the adjusted odds ratios for each outcome may be related to our small sample size and limited power to detect a true association. Nevertheless, the direction of the point estimates suggests increased harm with abciximab, not eptifibatide. Third, all hospitals participating in this registry are actively engaged in statewide collaborative quality improvement initiatives. As such, these findings may not be generalizable to hospitals that do not participate in such initiatives. 26 Lastly, we did not collect data on medication dosages or the timing of medication administration relative to the patient's subsequent dialysis session. This may have an important impact on the safety and efficacy of these drugs as prior research has demonstrated that medications are frequently dosed incorrectly in patients with renal insufficiency. 2, 11, 27 Furthermore, prior research suggests that hemodialysis can effectively reverse the antithrombotic effects of eptifibatide, potentially affecting the decision to use the drug and its impact on clinical outcomes.
14,28,29
Although eptifibatide is contraindicated in patients on dialysis, it was used approximately 3.5 times more often than abciximab during PCI.
However, in a propensity-matched analysis, we discovered similar safety outcomes between eptifibatide and abciximab among dialysis patients who underwent PCI. These findings suggest the need for further investigation into the reasons why eptifibatide continues to be used in this population and why there are no significant differences in outcomes.
